Journal List > Korean Circ J > v.19(3) > 1072508

TOOLS
Kim, Kim, Oh, Oh, Lee, Park, Choi, Seo, and Lee: Effect of Bezafibrate(Bezalip®)in Patients with Hyperlipidemia
Original Article
Korean Circulation Journal

Korean Circulation Journal 1989; 19(3): 497-502.

Published online: 30 September 1989

DOI: https://doi.org/10.4070/kcj.1989.19.3.497

Effect of Bezafibrate(Bezalip®)in Patients with Hyperlipidemia

Chee Jeong Kim, M.D., Young Dae Kim, M.D., Dong Jin Oh, M.D., Byung Hee Oh, M.D., Myoung Mook Lee, M.D., Young Bae Park, M.D., Yun Shik Choi, M.D., Jung Don Seo, M.D., Young Woo Lee, M.D.

Copyright © 1989 The Korean Society of Circulation

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

41 patients with hyperlipidemia(Serum cholesterol ≥260mg% or triglyceride≥200mg%) were treated for 12 weeks each with either Bezafibrate(200mg t.i.d.)(n=23) or placebo(n=18) in a randomized trial. Compared with placebo, Bezafibrate was more effective in lowing total cholesterol(287±63 to 244±32 mg%, P<0.01), LDL-cholesterol(183±39 to 153 ±25mg%, P<0.01) and the LDL/HDL ratio(4.7±2.9 to 3.4±1.3, P<0.05). There was also a marked reduction in serum triglyceride(307±295 to 218±167mg%, P<0.05) as well as a significant increase in HDL-cholesterol(43±12 to 48±12mg%, P<0.05).
Compliance or tolerance to both Bezafibrate and placebo was good. No significant side effects except one case, who complained of mild indigestion, were observed. Therefore, Bezafibrate seemed to be effective in lowing serum total cholesterol, LDL-cholestrol, triglyceride and in increasing in HDL-cholesterol without significant side effect.

Keywords: Bezafibrate, Hyperlipidemia

TOOLS
Similar articles